Brief: Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate
10/07/2026 16:19
BRIEF-Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate July 10 (Reuters) - TransThera Sciences (Nanjing) Inc 2617.HK:
NMPA APPROVES PHASE II TRIAL OF TT-973 WITH FIRMONERTINIB MESYLATE ON JULY 10, 2026
Further company coverage: 2617.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on TransThera Sciences (Nanjing)
See all newsBrief: Transthera Sciences (Nanjing) Says Yochanra (Tinengotinib) Included In CSCO Guidelines
TransThera at 6-week high on China regulator's nod to market cancer drug
Brief: TransThera Sciences (Nanjing) Says NMPA Grants Marketing Approval For Yochanra (Tinengotinib Tablets)
Brief: Transthera Sciences (Nanjing) Says NMPA Approves Phase II Trial Of TT-973 With Firmonertinib Mesylate
TransThera Sciences jumps most in nearly four months on share buyback plan